Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32647. [Epub ahead of print]
Plasma Circular RNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma: A Large-Scale, Multicenter Study.
Yu J1,2,3, Ding WB1,2,3, Wang MC1,2,3, Guo XG1,2,3, Xu J4, Xu QG1,2,3, Yang Y1,2,3, Sun SH5,6, Liu JF7, Qin LX8, Liu H1,2,3, Yang F5,6, Zhou WP1,2,3.
Author information
1
The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
2
Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU)，Ministry of Education, Shanghai 200438, China.
3
Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China.
4
Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University, Shanghai 200438, China.
5
Department of Medical Genetics, Second Military Medical University, Shanghai 200433, China.
6
Shanghai Key Laboratory of Cell Engineering (14DZ2272300), People's Republic of China.
7
Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, 350025, China.
8
Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China.
Abstract
To explore whether plasma circular RNAs (circRNAs) can diagnose hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), microarray and qPCR were used to identify plasma circRNAs that were increased in HBV-related HCC patients compared with controls (including healthy controls, chronic hepatitis B and HBV-related liver cirrhosis). A logistic regression model was constructed using a training set (n=313) and then validated using another two independent sets (n=306 and 526, respectively). Area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy. We identified a plasma circRNA panel (CircPanel) containing three circRNAs (hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897) that could detect HCC. CircPanel showed a higher accuracy than AFP (alpha-fetoprotein) to distinguish individuals with HCC from controls in all three sets (AUC 0.863 [95% CI 0.819-0.907] vs 0.790 [0.738-0.842], P=0.036 in training set; 0.843 [0.796-0.890] vs 0.747 [0.691-0.804], P=0.011 in validation set 1 and 0.864 [0.830-0.898] vs 0.769 [0.728-0.810], P<0.001 in validation set 2). CircPanel also performed well in detecting Small-HCC (solitary, ≤3cm), AFP-negative HCC and AFP-negative Small-HCC. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS: